![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
By Mauro Orru Bayer appointed Nelson Ambrogio as head of the radiology business under its pharmaceuticals division, succeeding Gerd Krueger who will retire after eight years at the helm of the...
By Pierre Bertrand Bayer said that its menopause drug Elinzanetant met the primary endpoints of its Oasis 1 and 2 Phase 3 studies. When compared with placebo, the drug showed a statistically...
A jury in Washington state ordered Bayer's Monsanto to pay $857 million to former students and parent volunteers of a school who claimed that exposure to some chemicals developed by the...
1513 GMT - Bayer is among the most mentioned companies across news items over the past 12 hours, according to Factiva data. Shares in the German pharmaceutical-and-agricultural group suffered...
By Adria Calatayud Bayer shares fell sharply after the company stopped a late-stage study for a cardiovascular drug early due to lack of efficacy and was ordered to pay $1.56 billion in a lawsuit...
By Helena Smolak Bayer is discontinuing early a Phase 3 study to test investigational drug asundexian on prevention of stroke and systemic embolism for patients with atrial fibrillation due to...
By Colin Kellaher German drugs-to-crops giant Bayer is pulling Aliqopa from the U.S. after a confirmatory trial of the lymphoma drug missed its primary endpoint. Bayer on Monday said it will work...
By Colin Kellaher Bayer on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of a high-dose formulation of the blockbuster...
By Mauro Orru Bayer Chief Executive Bill Anderson said he is looking at options to overhaul the company's structure and remove multiple layers of management in a move that will result in...
By Mauro Orru Bayer Chief Executive Bill Anderson said he is looking at options to overhaul the company's structure and remove multiple layers of management in a move that will result in...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 3.08 | 4.96453900709 | 62.04 | 65.12 | 62.04 | 30768 | 63.6647839 | DR |
4 | -1.54 | -2.3102310231 | 66.66 | 66.73 | 60.386 | 57818 | 63.47551565 | DR |
12 | -4.4025 | -6.33248228991 | 69.5225 | 74.39 | 60.386 | 51756 | 66.74566828 | DR |
26 | -1.01 | -1.52729472252 | 66.13 | 74.39 | 58.51 | 73576 | 64.29890921 | DR |
52 | -2.17 | -3.22484767425 | 67.29 | 74.39 | 55.37 | 70568 | 64.61624256 | DR |
156 | 6.28 | 10.6730115568 | 58.84 | 76.695 | 42.98 | 105991 | 60.45736805 | DR |
260 | -9.48 | -12.7077747989 | 74.6 | 87.69 | 37.69 | 95077 | 62.01586486 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions